Human African Trypanosomiasis

Manson's Tropical Diseases, Twenty-second Edition

Volumn , Issue , 2008, Pages 1307-1325

  Burri, Christian ^a   Brun, Reto ^a  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85159012075     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-4470-3.50079-3     Document Type: Chapter

References (118)

1. PAAT (Program Against African Trypanosomiasis). Information System. 2006. Online. Available: http://wwwfaoorg/paat/html/gishtm
2. DJ Rogers and BG Williams (1993) Monitoring trypanosomiasis in space and time. Parasitology 106(suppl), S77-S92.
3. AM Jordan (1986) Trypanosomiasis Control and African Rural Development London: Longman
4. WHO (1998) Control and surveillance of African trypanosomiasis Geneva: World Health Organization
5. PM Abel, G Kiala, V Loa, et al. (2004) Retaking sleeping sickness control in Angola. Trop Med Int Health 9(1), 141-148.
6. P Lutumba (2005) Trypanosomiasis control, democratic republic of Congo, 1993-2003. Emerg Infect Dis 11(9), 1382-1389.
7. J Robays, MM Bilengue, PV Stuyft, et al. (2004) The effectiveness of active population screening and treatment for sleeping sickness control in the Democratic Republic of Congo. Trop Med Int Health 9(5), 542-550.
8. JA Ruiz, PP Simarro and T Josenando (2002) Control of human African trypanosomiasis in the Quicama focus, Angola. Bull World Health Organ 80(9), 738-745.
9. PP Simarro, JR Franco, P Ndongo, et al. (2006) The elimination of Trypanosoma brucei gambiense sleeping sickness in the focus of Luba, Bioko Island, Equatorial Guinea. Trop Med Int Health 11(5), 636-646.
10. M Balasegaram, S Harris, F Checchi, et al. (2006) Treatment outcomes and risk factors for relapse in patients with early-stage human African trypanosomiasis (HAT) in the Republic of the Congo. Bull WHO 84 777-782.
11. Anonymous (2006) Weekly Epidemiological Record 8 71-80.
12. CA Hoare (1972) The Trypanosomes of Mammals (A Zoological Monograph) Oxford: Blackwell Scientific
13. K Vickerman (1978) Antigenic variation in trypanosomes. Nature 273(5664), 613-617.
14. P Buscher, SK Bin Shamamba, DM Ngoyi, et al. (2005) Susceptibility of Grammomys surdaster thicket rats to Trypanosoma brucei gambiense infection. Trop Med Int Health 10(9), 850-855.
15. N Inoue, D Narumi, PA Mbati, et al. (1998) Susceptibility of severe combined immuno-deficient (SCID) mice to Trypanosoma brucei gambiense and T. b. rhodesiense. Trop Med Int Health 3(5), 408-412.
16. P Truc, D Aerts, JJ McNamara, et al. (1992) Direct isolation in vitro of Trypanosoma brucei from man and other animals, and its potential value for the diagnosis of Gambian trypanosomiasis. Trans R Soc Trop Med Hyg 86(6), 627-629.
17. P Dukes, A Kaukas, KM Hudson, et al. (1989) A new method for isolating Trypanosoma brucei gambiense from sleeping sickness patients. Trans R Soc Trop Med Hyg 83(5), 636-639.
18. NW Maina, C Kunz and R Brun (2006) Cryopreservation of Trypanosoma brucei gambiense in a commercial cryomedium developed for bull semen. Acta Trop 98(3), 207-211.
19. NWN Maina, M Oberle, C Otieno, et al. (2007) Isolation and propagation of Trypanosoma brucei gambiense from sleeping sickness patients in South Sudan. Trans R Soc Trop Med Hyg 101(6), 540-546.
20. S Tomlinson and J Raper (1998) Natural human immunity to trypanosomes. Parasitol Today 14(9), 354-359.
21. E Pays, B Vanhollebeke, L Vanhamme, et al. (2006) The trypanolytic factor of human serum. Nat Rev Microbiol 4(6), 477-486.
22. LR Rickman and J Robson (1970) The blood incubation infectivity test: A simple test which may serve to distinguish Trypanosoma brucei from T. rhodesienses. Bull WHO 42(4), 650-651.
23. L Jenni and R Brun (1982) A new in vitro test for human serum resistance of Trypanosoma (T.) brucei. Acta Trop 39(3), 281-284.
24. M Radwanska, M Chamekh, L Vanhamme, et al. (2002) The serum resistance-associated gene as a diagnostic tool for the detection of Trypanosoma brucei rhodesiense. Am J Trop Med Hyg 67(6), 684-690.
25. M Berberof, D Perez-Morga and E Pays (2001) A receptor-like flagellar pocket glycoprotein specific to Trypanosoma brucei gambiense. Mol Biochem Parasitol 113(1), 127-138.
26. L Jenni, S Marti, J Schweizer, et al. (1986) Hybrid formation between African trypanosomes during cyclical transmission. Nature 322(6075), 173-175.
27. WC Gibson and VH Mizen (1997) Heritability of the trait for human infectivity in genetic crosses of Trypanosoma brucei ssp. Trans R Soc Trop Med Hyg 91(2), 236-237.
28. G Simo, S Herder, F Njiokou, et al. (2005) Trypanosoma brucei s.l.: characterisation of stocks from Central Africa by PCR analysis of mobile genetic elements. Exp Parasitol 110(4), 353-362.
29. O Balmer, C Palma, A MacLeod, et al. (2006) Characterization of di-, tri- and tetranucleotide microsatellite markers with perfect repeats for Trypanosoma brucei and related species. Molecular Ecology Notes 6 508-510.
30. M Tibayrenc, F Kjellberg and FJ Ayala (1990) A clonal theory of parasitic protozoa: the population structures of Entamoeba, Giardia, Leishmania, Naegleria, Plasmodium, Trichomonas, and Trypanosoma and their medical and taxonomical consequences. Proc Natl Acad Sci USA 87(7), 2414-2418.
31. W Gibson and MA Miles (1985) Application of new technologies to epidemiology. Brit Med Bull 41(2), 115-121.
32. DG Godfrey, RD Baker, LR Rickman, et al. (1990) The distribution, relationships and identification of enzymic variants within the subgenus Trypanozoon. Adv Parasitol 29 1-39.
33. JR Stevens and DG Godfrey (1992) Numerical taxonomy of Trypanozoon based on polymorphisms in a reduced range of enzymes. Parasitology 104 75-86.
34. JR Stevens, SM Lanham, R Allingham, et al. (1992) A simplified method for identifying subspecies and strain groups in Trypanozoon by isoenzymes. Ann Trop Med Parasitol 86(1), 9-28.
35. S Herder, G Simo, S Nkinin, et al. (2002) Identification of trypanosomes in wild animals from southern Cameroon using the polymerase chain reaction (PCR). Parasite 9(4), 345-349.
36. H Buyst (1977) The epidemiology of sleeping sickness in the historical Luangwa valley. Ann Soc Belge Med Trop 57(4-5), 349-359.
37. L MacLean, JE Chisi, M Odiit, et al. (2004) Severity of human African trypanosomiasis in East Africa is associated with geographic location, parasite genotype, and host inflammatory cytokine response profile. Infect Immun 72(12), 7040-7044.
38. R Geigy, PM Mwambu and M Kauffmann (1971) Sleeping sickness survey in Musoma district, Tanzania. IV. Examination of wild mammals as a potential reservoir for T. rhodesiense. Acta Trop 28(3), 211-220.
39. C De Greef, H Imberechts, G Matthyssens, et al. (1989) A gene expressed only in serum-resistant variants of Trypanosoma brucei rhodesiense. Mol Biochem Parasitol 36(2), 169-176.
40. HV Xong, L Vanhamme, M Chamekh, et al. (1998) A VSG expression site-associated gene confers resistance to human serum in Trypanosoma rhodesiense. Cell 95(6), 839-846.
41. RE Cibulskis (1992) Genetic variation in Trypanosoma brucei and the epidemiology of sleeping sickness in the Lambwe Valley, Kenya. Parasitology 104(Part 1), 99-109.
42. WC Gibson and BT Wellde (1985) Characterization of Trypanozoon stocks from the South Nyanza sleeping sickness focus in Western Kenya. Trans R Soc Trop Med Hyg 79(5), 671-676.
43. RJ Onyango, K van Hoeve and P de Raadt (1966) The epidemiology of T. rhodesiense sleeping sickness in Alego location, central Nyanza, Kenya. I. Evidence that cattle may act as reservoir hosts of trypanosomes infective to man. Trans R Soc Trop Med Hyg 60 175.
44. WC Gibson and JK Gashumba (1983) Isoenzyme characterization of some Trypanozoon stocks from a recent trypanosomiasis epidemic in Uganda. Trans R Soc Trop Med Hyg 77(1), 114-118.
45. DAT Baldry and MFB Chaudhuri (1980) Epidemiology of African trypanosomiasis. Insect Sci Appl 1(1), 85-93.
46. SC Welburn and I Maudlin (1999) Tsetse-trypanosome interactions: rites of passage. Parasitol Today 15(10), 399-403.
47. F Chappuis, L Loutan, P Simarro, et al. (2005) Options for field diagnosis of human African trypanosomiasis. Clin Microbiol Rev 18(1), 133-146.
48. E Magnus, T Vervoort and N Van Meirvenne (1978) A card agglutination test with stained trypanosomes (CATT) for the serological diagnosis of T.b. gambiense trypanosomiasis. Ann Soc Belge Med Trop 58 169-176.
49. F Chappuis, E Stivalello, K Adams, et al. (2004) Card agglutination test for trypanosomiasis (CATT) end-dilution titer and cerebrospinal fluid cell count as predictors of human African trypanosomiasis (Trypanosoma brucei gambiense) among serologically suspected individuals in Southern Sudan. Am J Trop Med Hyg 71 313-317.
50. WO Inojosa, I Augusto, Z Bisoffi, et al. (2006) Diagnosing human African trypanosomiasis in Angola using a card agglutination test: observational study of active and passive case finding strategies. BMJ 332(7556), 1479.
51. PP Simarro, JA Ruiz, JR Franco, et al. (1999 Dec) Attitude towards CATT-positive individuals without parasitological confirmation in the African Trypanosomiasis (T.b. gambiense) focus of Quicama (Angola). Trop Med Int Health 4(12), 858-861.
52. P Buscher, V Lejon, E Magnus, et al. (1999) Improved latex agglutination test for detection of antibodies in serum and cerebrospinal fluid of Trypanosoma brucei gambiense infected patients. Acta Trop 73(1), 11-20.
53. S Deborggraeve, F Claes, T Laurent, et al. (2006) Molecular dipstick test for diagnosis of sleeping sickness. J Clin Microbiol 44(8), 2884-2889.
54. PT Woo (1969) The haematocrit centrifuge for the detection of trypanosomes in blood. Can J Zool 47(5), 921-923.
55. WGR Lumsden, CD Kimber, DA Evans, et al. (1979) Trypanosoma brucei: Miniature anion exchange centrifugation for detection of low parasitemias: Adaptation for field use. Trans R Soc Trop Med Hyg 73 313-317.
56. F Doua, TW Miezan, JR Sanon Singaro, et al. (1996) The efficacy of pentamidine in the treatment of early-late stage Trypanosoma brucei gambiense trypanosomiasis. Am J Trop Med Hyg 55(6), 586-588.
57. V Lejon, D Legros, A Savignoni, et al. (2003) Neuro-inflammatory risk factors for treatment failure in ‘early second stage’ sleeping sickness patients treated with Pentamidine. J Neuroimmunol 144(1-2), 132-138.
58. V Lejon and P Buscher (2005) Cerebrospinal fluid in human African trypanosomiasis: a key to diagnosis, therapeutic decision and post-treatment follow-up [Review Article]. Trop Med Int Health 10(5), 395-403.
59. V Lejon, P Buscher, NH Sema, et al. (1998) Human African trypanosomiasis: A latex agglutination field test for quantifying IgM in cerebrospinal fluid. Bull WHO 76(6), 553-558.
60. V Lejon, D Legros, M Richer, et al. (2002) IgM quantification in the cerebrospinal fluid of sleeping sickness patients by a latex card agglutination test. Trop Med Int Health 7(8), 685-692.
61. A Buguet, S Bisser, T Josenando, et al. (2005) Sleep structure: a new diagnostic tool for stage determination in sleeping sickness. Acta Trop 93(1), 107-117.
62. J Blum, C Schmid and C Burri (2006) Clinical aspects of 2541 patients with second stage human African trypanosomiasis. Acta Trop 97(1), 55-64.
63. M Schultzberg, M Ambatsis, EB Samuelsson, et al. (1988) Spread of Trypanosoma brucei to the nervous system: early attack on circumventricular organs and sensory ganglia. J Neurosci Res 21(1), 56-61.
64. J Pepin (2000) African trypanosomiasis. GT Strickland (Eds) Hunter's Tropical Medicine and Emerging Infectious Diseases 8th edn. Philadelphia: Saunders 643-654.
65. PEC Manson-Bahr and DR Bell (1987) African Trypanosomiasis. Manson's Tropical Diseases 19th edn. London: Baillière and Tindall 54-73.
66. DH Molyneux, V Pentreath and F Doua (1996) African trypanosomiasis in man. GC Cook (Eds) Manson's Tropical Diseases 20th edn. London: Saunders 1171-1196.
67. K Kristensson and M Bentivoglio (1999) Pathology of African trypanosomiasis. M Dumas, B Bouteille, A Buguet (Eds) Progress in Human African Trypanosomiasis, Sleeping Sickness Paris: Springer 157-182.
68. JM Mansfield and DM Paulnock (2005) Regulation of innate and acquired immunity in African trypanosomiasis. Parasite Immunol 27(10-11), 361-371.
69. L MacLean, M Odiit and JM Sternberg (2001) Nitric oxide and cytokine synthesis in human African trypanosomiasis. J Infect Dis 184(8), 1086-1090.
70. PD Baetselier, B Namangala, W Noel, et al. (2001) Alternative versus classical macrophage activation during experimental African trypanosomosis. Int J Parasitol 31(5-6), 575-587.
71. V Lejon, H Reiber, D Legros, et al. (2003) Intrathecal immune response pattern for improved diagnosis of central nervous system involvement in trypanosomiasis. J Infect Dis 187(9), 1475-1483.
72. J Sternberg (2004) Human African trypanosomiasis: clinical presentation and immune response. Parasite Immunol 26(11-12), 469-476.
73. S Bisser, ON Ouwe-Missi-Oukem-Boyer, FS Toure, et al. (2006) Harbouring in the brain: A focus on immune evasion mechanisms and their deleterious effects in malaria and human African trypanosomiasis. Int J Parasitol 36(5), 529-540.
74. P Vincendeau and B Bouteille (2006) Immunology and immunopathology of African trypanosomiasis. An Acad Bras Cienc 78(4), 645-665.
75. M Berriman, E Ghedin, C Hertz-Fowler, et al. (2005) The genome of the African trypanosome Trypanosoma brucei. Science 309(5733), 416-422.
76. NM El-Sayed, PJ Myler, G Blandin, et al. (2005) Comparative genomics of trypanosomatid parasitic protozoa. Science 309(5733), 404-409.
77. OC Hutchinson, H Webb, K Picozzi, et al. (2004) Candidate protein selection for diagnostic markers of African trypanosomiasis. Trends Parasitol 20(11), 519-523.
78. D Agranoff, A Stich, P Abel, et al. (2005) Proteomic fingerprinting for the diagnosis of human African trypanosomiasis. Trends Parasitol 21(4), 154-157.
79. FIC Apted (1970) Treatment of human trypanosomiasis. HW Mulligan (Eds) The African Trypanosomiasis London: Allen & Unwin 684-710.
80. M Sands, MA Kron and RB Brown (1985) Pentamidine: A review. Review in Infectious Diseases 7 625-634.
81. F Doua and FB Yapo (1993) Human trypanosomiasis in the Ivory Coast - therapy and problems. Acta Trop 54(3-4), 163-168.
82. U Bronner, F Doua, O Ericsson, et al. (1991) Pentamidine concentrations in plasma, whole blood and cerebrospinal fluid during treatment of Trypanosoma gambiense infection in Côte d'Ivoire. Trans R Soc Trop Med Hyg 85(5), 608-611.
83. BJ Berger, RJ Lombardy, GD Marbury, et al. (1990) Metabolic N-hydroxylation of pentamidine in vitro. Antimicrob Agents Chemother 34(9), 1678-1684.
84. CC Wang (1995) Molecular mechanisms and therapeutic approaches to the treatment of African trypanosomiasis. Annu Rev Pharmacol Toxicol 35 93-127.
85. JM Collins, RWJ Klecker, R Yarchoan, et al. (1986) Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. J Clin Pharmacol 26 22-26.
86. CP Chijioke, RE Umeh, AU Mbah, et al. (1998) Clinical pharmacokinetics of suramin in patients with onchocerciasis. Eur J Clin Pharmacol 54(3), 249-251.
87. AH Fairlamb and BR Bowman (1980) Uptake of the trypanocidal drug suramin by bloodstream forms of Trypanosoma brucei and its effect in respiration and growth rate in vivo. J Biochem Pathol 1 315-333.
88. EAH Friedheim (1949) Mel B in the treatment of human trypanosomiasis. Am J Trop Med Hyg 29 173-180.
89. R Brun, R Schumacher, C Schmid, et al. (2001) The phenomenon of treatment failures in human African trypanosomiasis. Trop Med Int Health 6(11), 906-914.
90. C Burri, S Nkunku, A Merolle, et al. (2000) Efficacy of new, concise treatment schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet 355 1419-1425.
91. C Schmid, M Richer, CM Bilenge, et al. (2005) Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: Confirmation from a multinational study (Impamel II). J Infect Dis 191(11), 1922-1931.
92. J Jannin and P Cattand (2004) Treatment and control of human African trypanosomiasis. Curr Opin Infect Dis 17(6), 565-571.
93. J Blum, S Nkunku and C Burri (2001) Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis. Trop Med Int Health 6(5), 390-400.
94. SL Soignet, WP Tong, S Hirschfeld, et al. (1999) Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia. Cancer Chemother Pharmacol 44(5), 417-421.
95. J Keiser, O Ericsson and C Burri (2000) Investigations of the metabolites of the trypanocidal drug melarsoprol. Clin Pharmacol Therapeutics 67(5), 478-488.
96. J Pepin, F Milord, B Mpia, et al. (1989) An open clinical trial of nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness in central Zaire. Trans R Soc Trop Med Hyg 83(4), 514-517.
97. S Van Nieuwenhove (1999) Present strategies in the treatment of human African trypanosomiasis. M Dumas, B Bouteille, A Buguet (Eds) Progress in Human African Trypanosomiasis, Sleeping Sickness Paris: Springer 253-280.
98. C Burri, T Baltz, C Giroud, et al. (1993) Pharmacokinetic properties of the trypanocidal drug melarsoprol. Chemotherapy 39(4), 225-234.
99. F Chappuis, N Udayraj, K Stietenroth, et al. (2005) Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis. Clin Infect Dis 41(5), 748-751.
100. C Burri and R Brun (2003) Eflornithine for treatment of human African trypanosomiasis. Parasitol Res 90(suppl 1), S49-S52.
101. MM Dow (1991) Ornidyl label. Ornidyl Patient Information
102. CJ Bacchi, HC Nathan, SH Hutner, et al. (1980) Polyamine metabolism: a potential therapeutic target in trypanosomes. Science 210(4467), 332-334.
103. AE Pegg and PP McCann (1982) Polyamine metabolism and function. Am J Physiol 243(5), C212-C221.
104. R Gonnert (1972) Nifurtimox: causal treatment of Chagas' disease. Drug Res 22(9), 1563.
105. G Priotto, C Fogg, M Balasegaram, et al. (2006) Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: A randomized clinical trial in Uganda. PLoS Clin Trials 1(8), e39. 1-8.
106. DH Wegner and RW Rohwedder (1972) Experience with nifurtimox in chronic Chagas' infection. Preliminary report. Drug Res 22(9), 1635-1641.
107. C Paulos, J Paredes, I Vasquez, et al. (1989) Pharmacokinetics of a nitrofuran compound, nifurtimox, in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 27(9), 454-457.
108. R Docampo and SN Moreno (1986) Free radical metabolism of antiparasitic agents. Fed Proc 45(10), 2471-2476.
109. D Legros, S Evans, F Maiso, et al. (1999) Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Trans R Soc Trop Med Hyg 93 439-442.
110. A Stanghellini and T Josenando (2001) The situation of sleeping sickness in Angola: a calamity. Trop Med Int Health 6(5), 330-334.
111. J Pepin and B Mpia (2005) Trypanosomiasis relapse after melarsoprol therapy, Democratic Republic of Congo, 1982-2001. Emerg Infect Dis 11(6), 921-927.
112. C Burri and J Keiser (2001) Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment. Trop Med Int Health 6(5), 412-420.
113. E Matovu, JC Enyaru, D Legros, et al. (2001) Melarsoprol refractory T.b. gambiense from Omugo, north-western Uganda. Trop Med Int Health 6(5), 407-411.
114. E Matovu, F Geiser, V Schneider, et al. (2001) Genetic variants of the TbAT1 adenosine transporter from African trypanosomes in relapse infections following melarsoprol therapy. Mol Biochem Parasitol 117(1), 73-81.
115. Bisser S, Van Nieuwenhove S, Lejon V, et al. New therapeutic regimen for sleeping sickness. Description, results and lessons from the clinical trial established in Bwamanda (Equateur, RDC). Bruges: COST B9 Meeting; 2000.
116. Immtech Immtech Report Fiscal Year End 2008 Results. Online. Available: http://www.immtechpharma.com/documents/news_061808a.pdf
117. Anonymous. $22.6 Million Gates Foundation Grant Targets New Treatment for African Sleeping Sickness. 2006. Online. Available: http://wwwuncedu/news/archives/may06/may06shtml
118. B Bouchet, D Legros and E Lee (1998) Key indicators for the monitoring and evaluation of control programmes of human African trypanosomiasis due to Trypanosoma brucei gambiense. Trop Med Int Health 3(6), 474-481.